Bispecific antibodies in multiple myeloma treatment: A journey in progress

被引:24
|
作者
Cho, Shih-Feng [1 ,2 ,3 ]
Yeh, Tsung-Jang [1 ]
Anderson, Kenneth C. [4 ,5 ]
Tai, Yu-Tzu [4 ,5 ]
机构
[1] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Kaohsiung, Taiwan
[2] Kaohsiung Med Univ, Coll Med, Fac Med, Kaohsiung, Taiwan
[3] Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung, Taiwan
[4] Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
[5] Harvard Med Sch, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
multiple myeloma; immunotherapy; bispecific antibody; bispecific T-cell engager; BCMA; GPRC5D; FcRH5; CD38; CELL MATURATION ANTIGEN; PRECLINICAL ACTIVITY; DEXAMETHASONE; MICROENVIRONMENT; EFFICACY; LENALIDOMIDE; BORTEZOMIB; OUTCOMES; CD3; IMMUNOTHERAPY;
D O I
10.3389/fonc.2022.1032775
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The incorporation of novel agents and monoclonal antibody-based therapies into the treatment of multiple myeloma (MM) has significantly improved long-term patient survival. However, the disease is still largely incurable, with high-risk patients suffering shorter survival times, partly due to weakened immune systems. Bispecific molecules, including bispecific antibodies (BisAbs) and bispecific T-cell engagers (BiTEs), encourage immune cells to lyse MM cells by simultaneously binding antigens on MM cells and immune effector cells, bringing those cells into close proximity. BisAbs that target B-cell maturation antigen (BCMA) and GPRC5D have shown impressive clinical activity, and the results of early-phase clinical trials targeting FcRH5 in patients with relapsed/refractory MM (RRMM) are also promising. Furthermore, the safety profile of these agents is favorable, including mainly low-grade cytokine release syndrome (CRS). These off-the-shelf bispecific molecules will likely become an essential part of the MM treatment paradigm. Here, we summarize and highlight various bispecific immunotherapies under development in MM treatment, as well as the utility of combining them with current standard-of-care treatments and new strategies. With the advancement of novel combination treatment approaches, these bispecific molecules may lead the way to a cure for MM.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Bispecific Antibodies for the Treatment of Multiple Myeloma
    Scott R. Goldsmith
    Shawn Streeter
    Fahrettin Covut
    [J]. Current Hematologic Malignancy Reports, 2022, 17 : 286 - 297
  • [2] Bispecific Antibodies for the Treatment of Multiple Myeloma
    Goldsmith, Scott R.
    Streeter, Shawn
    Covut, Fahrettin
    [J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2022, 17 (06) : 286 - 297
  • [3] Bispecific Antibodies in the Treatment of Multiple Myeloma
    Zhou, Xiang
    Xiao, Xianghui
    Kortuem, Klaus Martin
    Einsele, Hermann
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2024, 38 (02) : 361 - 381
  • [4] Bispecific antibodies in the treatment of multiple myeloma
    Devasia, Anup Joseph
    Chari, Ajai
    Lancman, Guido
    [J]. BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [5] Bispecific antibodies in multiple myeloma
    Escure, Guillaume
    Manier, Salomon
    [J]. BULLETIN DU CANCER, 2021, 108 (10) : S205 - S212
  • [6] Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma
    Zhou, Xiang
    Einsele, Hermann
    Danhof, Sophia
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (07) : 1 - 14
  • [7] Bispecific Antibodies in Multiple Myeloma: Present and Future
    Lancman, Guido
    Sastow, Dahniel L.
    Cho, Hearn J.
    Jagannath, Sundar
    Madduri, Deepu
    Parekh, Samir S.
    Richard, Shambavi
    Richter, Joshua
    Sanchez, Larysa
    Chari, Ajai
    [J]. BLOOD CANCER DISCOVERY, 2021, 2 (05): : 423 - 433
  • [8] Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives
    Parrondo, Ricardo D.
    Ailawadhi, Sikander
    Cerchione, Claudio
    [J]. FRONTIERS IN ONCOLOGY, 2024, 14
  • [9] Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma
    Tacchetti, Paola
    Barbato, Simona
    Mancuso, Katia
    Zamagni, Elena
    Cavo, Michele
    [J]. CANCERS, 2024, 16 (13)
  • [10] Current use of bispecific antibodies to treat multiple myeloma
    Lee, Holly
    Neri, Paola
    Bahlis, Nizar J.
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2023, (01) : 332 - 339